Lung neuroendocrine neoplasm

This phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…

This Phase 3 trial tests whether a radioactive drug called 177Lu-edotreotide works better than the standard drug everolimus for people with advanced neuroendocrine tumors of the lung or thymus. About 170 participants will receive either six cycles of the radioactive therapy or da…

This study tests whether adding chemotherapy to surufatinib works better than surufatinib alone for people with a rare lung cancer called pulmonary neuroendocrine tumor. About 96 adults will be randomly assigned to one of two treatment groups. The goal is to see if the combinatio…

This study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…

This study looks at medical records from 34 people with advanced, well-differentiated high-grade neuroendocrine tumors in the lung, thymus, or pancreas. The goal is to see if these tumors behave differently and how they are treated. By comparing outcomes, researchers hope to find…

This study aims to find out what factors might increase the risk of developing neuroendocrine tumors, a rare type of cancer. Researchers will analyze health records from over 14,000 people in Bavaria, Germany, looking at things like smoking, diabetes, and even depression. The goa…